Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) EBITDA (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed EBITDA for 13 consecutive years, with -$113719.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 231.04% year-over-year to -$113719.0, compared with a TTM value of -$393343.0 through Nov 2025, up 28.62%, and an annual FY2025 reading of -$313976.0, up 54.84% over the prior year.
  • EBITDA was -$113719.0 for Q4 2025 at CNBX Pharmaceuticals, up from -$150109.0 in the prior quarter.
  • Across five years, EBITDA topped out at $2.1 million in Q1 2021 and bottomed at -$2.6 million in Q1 2023.
  • Average EBITDA over 5 years is -$494099.7, with a median of -$251991.0 recorded in 2023.
  • The sharpest move saw EBITDA surged 170.24% in 2021, then crashed 231.04% in 2025.
  • Year by year, EBITDA stood at -$1.6 million in 2021, then skyrocketed by 73.97% to -$417539.0 in 2022, then soared by 57.24% to -$178523.0 in 2023, then soared by 80.76% to -$34352.0 in 2024, then plummeted by 231.04% to -$113719.0 in 2025.
  • Business Quant data shows EBITDA for CNBX at -$113719.0 in Q4 2025, -$150109.0 in Q3 2025, and -$59727.0 in Q2 2025.